Last reviewed · How we verify
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Details
| Lead sponsor | Amgen |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 12301 |
| Start date | Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jul 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Coronary Heart Disease (CHD)
Interventions
- Evolocumab
- Placebo
Countries
Italy, Finland, Taiwan, Poland, South Korea, Denmark, Netherlands, Russia, Belgium, Sweden, Estonia, Mexico, Lithuania, Bulgaria, Portugal, United States, Latvia, France, Slovakia, Greece, Austria, Hungary, Argentina, Canada, Romania, Iceland, Brazil, Spain, Ukraine, United Kingdom